tiprankstipranks
IDEX Corporation (IEX)
NYSE:IEX
Want to see IEX full AI Analyst Report?

IDEX (IEX) AI Stock Analysis

380 Followers

Top Page

IEX

IDEX

(NYSE:IEX)

Select Model
Select Model
Select Model
Outperform 75 (OpenAI - 5.2)
Rating:75Outperform
Price Target:
$253.00
▲(13.32% Upside)
Action:Reiterated
Date:07/29/26
Overall score reflects strong fundamentals and a notably positive earnings update: durable free cash flow, manageable leverage, and raised 2026 guidance supported by strong order momentum and ongoing buybacks. These strengths are partially offset by a relatively expensive valuation (P/E ~33) and some evidence of margin compression versus prior peak years, while the technical trend is positive but lacks supporting momentum indicator data.
Positive Factors
Strong free cash flow generation
Consistent, large FCF supports durable capital flexibility: funds buybacks, dividends, debt paydown, bolt-on M&A and targeted capex without relying on external financing. High cash conversion underpins long-term shareholder returns and resilience through industrial cycles.
Negative Factors
Margin compression versus prior peaks
Material step-down in margins versus recent peaks suggests lasting pricing, mix or cost pressures. Lower margins reduce intrinsic earnings power and ROE, requiring sustained productivity or higher-margin sales to restore historical profitability levels over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow generation
Consistent, large FCF supports durable capital flexibility: funds buybacks, dividends, debt paydown, bolt-on M&A and targeted capex without relying on external financing. High cash conversion underpins long-term shareholder returns and resilience through industrial cycles.
Read all positive factors

IDEX Key Performance Indicators (KPIs)

Any
Any
Revenue By Segment
Revenue By Segment
Analyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Chart InsightsIDEX's Health & Science Technologies segment shows resilience with record orders and margin expansion, driven by pharmaceuticals and data centers. Despite a dip in sales, the Fire & Safety/Diversified Products segment faces challenges from soft volumes and macroeconomic pressures. Fluid & Metering Technologies maintains stability with organic growth. The company's strategic acquisitions and robust liquidity position it well for future growth, despite ongoing market challenges. The narrowing of EPS guidance reflects confidence in the HST segment's strength and FMT's stability, while addressing FSDP's current hurdles.
Data provided by:The Fly

IDEX (IEX) vs. SPDR S&P 500 ETF (SPY)

IDEX Business Overview & Revenue Model

Company Description
IDEX Corporation is an international enterprise specializing in engineered solutions across diverse sectors. The company operates through three primary business units: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and F...
How the Company Makes Money
IDEX makes money primarily by selling engineered products and systems across its operating segments to OEMs, distributors, and end users. Revenue is largely generated from (1) equipment and component sales: higher-value, specialized pumps, valves,...

IDEX Earnings Call Summary

Earnings Call Date:Jul 29, 2026
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Oct 27, 2026
Earnings Call Sentiment Positive
The call conveyed strong underlying operational performance and demand momentum, with multiple material positives: organic revenue and EPS growth, significant order expansion (28% overall; HST 47%), margin expansion, record orders and improved leverage and cash generation. Management raised full-year guidance and endorsed continued share repurchases while increasing targeted CapEx to support visible future volumes. Key headwinds were limited: segment-level softness in FMT and FSDP (small or single-digit revenue impacts and margin compression from mix/volume deleverage), and a one-time reporting effect from tariff refunds that reduced reported organic growth by ~2% but provided margin/earnings benefit. Overall the positives materially outweigh the challenges.
Positive Updates
Revenue and Earnings Growth
Consolidated organic sales grew 5% year-over-year in Q2 2026; adjusted EPS increased 12% to $2.32 and adjusted gross margin expanded 110 basis points to 46.4%.
Negative Updates
Fluid & Metering Technologies (FMT) Mixed Performance
FMT organic orders grew 11% but organic sales only increased 1% year-over-year in Q2; FMT adjusted EBITDA margin declined ~20 basis points due to unfavorable mix despite tariff-related margin benefits. Some end-market softness noted in agriculture, chemical and energy.
Read all updates
Q2-2026 Updates
Negative
Revenue and Earnings Growth
Consolidated organic sales grew 5% year-over-year in Q2 2026; adjusted EPS increased 12% to $2.32 and adjusted gross margin expanded 110 basis points to 46.4%.
Read all positive updates
Company Guidance
IDEX raised its 2026 outlook, now forecasting full‑year organic revenue growth of 5–6% (up from 3–4%), driven by roughly low‑double‑digit growth in HST and slight year‑over‑year gains in FMT and FSDP; adjusted EBITDA margin is now guided to 27.0–27.3% (up from 26.5–27%) and adjusted EPS to $8.70–$8.85 (was $8.35–$8.55), implying high‑single‑digit to low‑double‑digit EPS growth. For Q3 the company expects 5–7% organic growth, adjusted EBITDA margin of 27–27.5% and adjusted EPS of $2.20–$2.25. Management increased 2026 capital expenditures to approximately $110M (from $90M), plans to maintain share repurchases at ~ $75M per quarter (Q2 buybacks were $77M), and noted Q2 cash metrics of $177M free cash flow, >$1.1B liquidity, and gross leverage down to 1.9x (from 2.1x); they also disclosed the Q2 IEEPA tariff refunds provided a $0.08 benefit to adjusted EPS and ~130 bps to adjusted EBITDA margin, and said stronger orders (organic orders +28% in Q2) and backlog supported the raised guidance.

IDEX Financial Statement Overview

Summary
Financial quality is above average, led by strong cash generation (TTM operating cash flow ~$717M vs. net income coverage ~1.34x and free cash flow ~$642M). Profitability remains solid (TTM gross margin ~44%, net margin ~14%), but margin compression versus 2022–2023 peaks and lower ROE (~12–13% vs. ~17–19% historically) temper the score; leverage is manageable (debt-to-equity ~0.46).
Income Statement
74
Positive
Balance Sheet
72
Positive
Cash Flow
85
Very Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.59B3.46B3.27B3.27B3.18B2.76B
Gross Profit1.60B1.54B1.52B1.62B1.59B1.36B
EBITDA904.40M903.50M859.40M964.10M909.80M720.50M
Net Income519.50M483.20M505.00M596.10M586.90M449.40M
Balance Sheet
Total Assets6.93B6.93B6.75B5.87B5.51B4.92B
Cash, Cash Equivalents and Short-Term Investments621.30M580.00M620.80M534.30M430.20M900.70M
Total Debt1.86B1.85B1.99B1.45B1.59B1.30B
Total Liabilities2.92B2.90B2.95B2.32B2.47B2.11B
Stockholders Equity4.01B4.03B3.79B3.54B3.04B2.80B
Cash Flow
Free Cash Flow641.50M616.80M603.00M626.80M489.40M492.60M
Operating Cash Flow716.70M680.40M668.10M716.70M557.40M565.30M
Investing Cash Flow-155.80M-137.60M-1.01B-283.80M-917.20M-698.10M
Financing Cash Flow-491.50M-632.60M465.90M-344.70M-37.80M-9.50M

IDEX Technical Analysis

Technical Analysis Sentiment
Positive
Last Price223.27
Price Trends
50DMA
222.74
Positive
100DMA
212.12
Positive
200DMA
198.21
Positive
Market Momentum
MACD
3.78
Negative
RSI
61.69
Neutral
STOCH
61.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IEX, the sentiment is Positive. The current price of 223.27 is below the 20-day moving average (MA) of 227.54, above the 50-day MA of 222.74, and above the 200-day MA of 198.21, indicating a bullish trend. The MACD of 3.78 indicates Negative momentum. The RSI at 61.69 is Neutral, neither overbought nor oversold. The STOCH value of 61.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IEX.

IDEX Risk Analysis

IDEX disclosed 1 risk factors in its most recent earnings report. IDEX reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

IDEX Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$12.86B24.5820.27%1.46%4.58%12.51%
75
Outperform
$16.59B31.6517.12%1.11%7.37%20.50%
75
Outperform
$16.99B33.0612.91%1.29%7.32%12.36%
75
Outperform
$17.52B34.3810.35%0.75%16.63%-9.75%
66
Neutral
$12.33B36.8716.19%0.43%13.85%8.45%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
58
Neutral
$11.60B44.709.54%0.61%-27.77%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IEX
IDEX
234.46
79.24
51.05%
GNRC
Generac Holdings
212.22
15.70
7.99%
GGG
Graco
83.54
1.54
1.88%
ITT
ITT
213.13
48.77
29.68%
NDSN
Nordson
310.11
102.23
49.18%
CR
Crane Company
219.88
26.51
13.71%

IDEX Corporate Events

Executive/Board ChangesShareholder Meetings
IDEX Shareholders Back Board, Executive Pay and Auditor
Positive
May 8, 2026
On May 6, 2026, IDEX Corporation held its Annual Meeting of Stockholders, at which shareholders elected four Class I directors — Mark A. Beck, Carl R. Christenson, Katrina L. Helmkamp and Alejandro Quiroz Centeno — to three-year terms ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 29, 2026